Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 9/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25449340 | 0.75 | NOS3 (0.36) | HSD17B10NOS3NOS1NOS2PDPK1 | |
| SCHEMBL24506887 | 0.75 | NOS3 (0.36) | HSD17B10NOS3NOS1NOS2PDPK1 | |
| SCHEMBL24506808 | 0.74 | FGFR1 (0.41) | HSD17B10NOS3NOS1NOS2EGFR | |
| SCHEMBL24506820 | 0.72 | HSD17B10 (0.39) | HSD17B10FGFR1 | |
| SCHEMBL31375796 | 0.71 | LATS1 (0.42) | KDM4E | |
| SCHEMBL26424915 | 0.70 | MCHR1 (0.44) | HSD17B10MCHR1EGFRKDM4E | |
| SCHEMBL24506569 | 0.70 | GAA (0.39) | NOS3NOS1NOS2PDPK1ALOX5AP | |
| SCHEMBL24506563 | 0.69 | GAA (0.40) | ALOX5APKDM4ESRC | |
| SCHEMBL24506813 | 0.67 | DHFR (0.41) | HSD17B10KDM4E | |
| SCHEMBL24506818 | 0.67 | KDM4E (0.50) | HSD17B10NOS3NOS1NOS2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20220185792-A1 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185792-A1 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | HSD17B10 2879/4885NOS3 1790/4885NOS1 1223/4885 |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | HSD17B10 2879/4885NOS3 1790/4885NOS1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.